For Health Care Professionals Outside the US US Residents VOTRIENT Summary of Product Characteristics Safety Information

VOTRIENT—Continuous once-daily oral dosing1

Treatment with VOTRIENT is consistent

Continuous dosing schedule

Dosing recommendations for VOTRIENT1

800 mg once-daily recommended dose
Taken whole with water (not broken or crushed)
Without food (at least 1 hour before or 2 hours after a meal)
200 mg dose modifications (based on individual tolerability to manage adverse events)

VOTRIENT dose should not exceed 800 mg daily

See prolonged progression-free survival
See head-to-head first-line data in advanced RCC
Reference: 1. VOTRIENT [summary of product characteristics]. Camberley, UK: Novartis Europharm Limited; February 2018.
Privacy Site Map Contact Us Summary of Product Characteristics Safety Information

Disclaimer: This is an international website for VOTRIENT® (pazopanib) and is intended for health care professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

© 2018 Novartis AG | Use of this website is subject to our Terms of Use